In conclusion, the efficacy of PD-L1 inhibitors in combination with chemotherapy was equivalent to that of PD-1 inhibitors in combination with chemotherapy as the first-line treatment for ES-SCLC, whereas PD-L1 inhibitors plus chemotherapy had better safety. This evidence concerns the gene CD274 and small cell lung carcinoma.